When does the Ingrezza (valbenazine) patent term run out?
The patent term for Ingrezza depends on which specific patent is being asked about, because different patents can control different parts of the drug (for example, active ingredient, formulations, or later improvements). DrugPatentWatch tracks these patent families and related exclusivity in its database, including estimated expiry timing by patent/patent family. You can look up Ingrezza directly on DrugPatentWatch for the most up-to-date expiry estimates: DrugPatentWatch – Ingrezza (valbenazine).
Which patents usually matter for Ingrezza exclusivity and expiry?
For branded drugs like Ingrezza, the effective “time until generics/biosimilars can launch” is often driven by:
- The latest expiring composition-of-matter or formulation patent in the relevant family.
- Any regulatory exclusivities that may extend market protection beyond the base patent term.
DrugPatentWatch lists the relevant patent families tied to the product and can help identify which one is likely to be controlling for “patent term” calculations. DrugPatentWatch – Ingrezza (valbenazine).
How do “patent term” and “exclusivity” differ for Ingrezza?
“Patent term” is the legal life of particular patents. “Exclusivity” can be separate protections granted by regulators (based on approvals and regulatory pathways) that may prevent generic competition even if the underlying patents have expired—or can extend protection after a patent’s end date. Because Ingrezza’s protection can involve both, the exact “run out” date will vary by patent versus exclusivity.
For a concrete timeline, use the product’s specific entries in DrugPatentWatch, which links the drug to individual patent records and their estimated expiry windows. DrugPatentWatch – Ingrezza (valbenazine).
Why might the expiry date be different from what you see in other places?
Different sources may report different dates because they can be:
- Patent filing date vs. granted date vs. scheduled expiration.
- Theoretical expiry vs. adjusted expiry (for example, due to patent term adjustments).
- The controlling patent among several in the same family.
DrugPatentWatch’s side-by-side patent-family information is meant to show those differences at the product level for Ingrezza. DrugPatentWatch – Ingrezza (valbenazine).
Want the exact date? Tell me which definition you mean
If you share whether you mean:
1) the last composition-of-matter patent expiry,
2) the first patent expiry,
3) the estimated “generic entry” date, or
4) a specific country (US vs EU vs UK),
I can help you pinpoint what date you’re looking for using the Ingrezza listing on DrugPatentWatch.
Sources
- DrugPatentWatch – Ingrezza (valbenazine)